Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo

Experimental Hematology

Volumn 38, Issue 8, 2010, Pages 666-676

  Yang, Jing ^a   Ikezoe, Takayuki ^a   Nishioka, Chie ^a   Ni, Lei ^a   Koeffler, H Phillip ^b   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CD11B ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EVEROLIMUS; HISTONE H3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE ANTIGEN; PROTEIN KINASE B; S6 KINASE; VITAMIN D RECEPTOR;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN U937; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ACETYLATION; ANIMALS; ANTIGENS, CD11B; CALCITRIOL; CELL CYCLE; CELL DIFFERENTIATION; COLONY-FORMING UNITS ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROMOTER REGIONS, GENETIC; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; U937 CELLS; VITAMINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MURINAE; MUS MUSCULUS;

EID: 77954529603     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.03.020     Document Type: Article

References (47)

1. Takashi K., Lee Y.S., Hughes S.V., et al. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005, 65:2489-2497.
2. Colstone K.W., Chander S.K., Mackay A.G., Coombes R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vitro and in vivo. Biochemical Pharm 1992, 44:693-702.
3. Shabahang M., Buras R.R., Davoodi F., Schumaker L.M., Nauta R.J., Evans S.R.T. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993, 53:3712-3718.
4. Eisman J.A., Barkla D.H., Tutton P.J.M. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987, 47:21-25.
5. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996, 10:142-153.
6. Rots N.Y., Iavarone A., Bromleigh V., Freedman L.P. Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999, 93:2721-2729.
7. Elstner E., Campbell M.J., Munker R., et al. Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 1999, 40:141-149.
8. Muto A., Kizaki M., Yamato K., et al. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood 1999, 93:2225-2233.
9. Munker R., Kobayashi T., Elstner E., et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996, 88:2201-2209.
10. Wang J.R., Zhao Y., Kauss M.A., Spindel S., Lian H. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur J Cell Biol 2009, 88:103-115.
11. O'Kelly J., Uskokovic M., Lemp N., Vadgama J., Koeffler H.P. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J Steroid Biochem Mol Biol 2000, 100:107-116.
12. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
13. Inoki K., Li K., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002, 4:648-657.
14. Bjornsti M.A., Houghton P.J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004, 5:519-523.
15. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
16. Jacinto E., Loewith R., Schmidt A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
17. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
18. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
19. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008, 22:2159-2168.
20. Nishioka C., Ikezoe T., Yang J., Gery S., Koeffler H.P., Yokoyama A. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009, 125:1710-1720.
21. Chan S. Targeting the mammalian target of rapamycin(mTOR): a new approach to treating cancer. Br J Cancer 2004, 91:1420-1424.
22. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., Koeffler H.P. Antiproliferative activity of RAD001(everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21:333-339.
23. Munker P., Kobayashi T., Elstner E., et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996, 88:2201-2209.
24. Ikezoe T., Nishioka C., Tasaka T., et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006, 5:2522-2530.
25. Ikezoe T., Tanosaki S., Krug U., et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004, 104:237-242.
26. Nishioka C., Ikezoe T., Yang J., Koeffler H.P., Yokoyama A. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21(waf1) promoter in acute myelogenous leukemia cell. Leukemia 2008, 22:1449-1452.
27. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000, 97:10014-10019.
28. Nishio H., Walsh M.J. CCAAT displacement protein/cut homolog recruits G9a histone lysine methyltransferase to repress transcription. Proc Natl Acad Sci U S A 2004, 101:11257-11262.
29. Nagaki K., Talbert P.B., Zhong C.X., Dawe R.K., Henikoff S., Jiang J. Chromatin immunoprecipitation reveals that the 180-bp satellite repeat is the key functional DNA element of Arabidopsis thaliana centromeres. Genetics 2003, 163:1221-1225.
30. Ikezoe T., Yang Y., Bandobashi K., et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005, 4:578-586.
31. Archer S.Y., Hodin R.A. Histone acetylation and cancer. Curr Opin Genet Dev 1999, 9:171-174.
32. Pepper C., Thomas A., Hoy A., Milligan D., Bentley P., Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003, 101:24554-24560.
33. Hickish T., Cunningham D., Colston K., et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of the vitamin D receptor in lymphoma. Br J Cancer 1993, 68:668-672.
34. Koeffler H.P., Aslanian N., O'Kelly J. Vitamin D2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leukemia Res 2005, 29:1259-1262.
35. Amir E., Simmons C.E., Freedman O.C., et al. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 2010, 116:284-291.
36. Wietrzyk J., Nevozhay D., Filip B., Milczarek M., Kutner A. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res 2007, 27:3387-3398.
37. Chiang K.C., Persons K.S., Istfan N.W., Holick M.F., Chen T.C. Fish oil enhances the antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res 2009, 29:3591-3596.
38. Park S.J., Kim M., Kim N.H., et al. Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br J Pharmacol 2008, 154:1196-1205.
39. Marderosian M., Sharma A., Funk A.P., et al. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006, 25:6277-6290.
40. Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen sythase kinase-3 controls c-Myc proteolysis and subnuclear localization. J Biol Chem 2003, 278:51606-51612.
41. Gera J.F., Mellingghoff I.K., Shi Y., et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-Myc expression. J Biol Chem 2004, 279:2737-2746.
42. Wall M., Poortinga G., Hannan K.M., Pearson R.B., Hannan R.D., McArthur G.A. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 2008, 112:2305-2317.
43. Polek T.C., Stewart L.V., Ryu E.J., Cohen M.B., Allegretto E.A., Weigel N.L. p53 is required for 1,25-dihydroxyvitamin D3-inducedG0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003, 144:50-60.
44. Malone J.M., Deppe G. Inhibition of c- myc in breast and ovarian carcinoma cells by 1, 25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993, 4:201-208.
45. Tong W.M., Kallay E., Hofer H., et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1, 25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998, 34:2119-2125.
46. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
47. Zent C.S., Laplant B.R., Johnston P.B., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116:2201-2207.